26 THE INTESTINAL MICROBIOME IN INFLAMMATORY BOWEL DISEASE ACROSS THE PEDIATRIC AGE RANGE

2019 ◽  
Vol 156 (3) ◽  
pp. S102-S103
Author(s):  
Maire A. Conrad ◽  
Kyle Bittinger ◽  
Yue Ren ◽  
Jessica Breton ◽  
Nina Devas ◽  
...  
2019 ◽  
Vol 156 (6) ◽  
pp. S-394
Author(s):  
Maire A. Conrad ◽  
Kyle Bittinger ◽  
Yue Ren ◽  
Nina Devas ◽  
Hongzhe Li ◽  
...  

2019 ◽  
Vol 25 (Supplement_1) ◽  
pp. S70-S70
Author(s):  
Maire A Conrad ◽  
Kyle Bittinger ◽  
Yue Ren ◽  
Jessica Breton ◽  
Nina Devas ◽  
...  

2010 ◽  
Vol 72 (1) ◽  
pp. 95-102 ◽  
Author(s):  
M. Kyle Jensen ◽  
Neelesh A. Tipnis ◽  
Ruta Bajorunaite ◽  
Mehul K. Sheth ◽  
Thomas T. Sato ◽  
...  

JGH Open ◽  
2020 ◽  
Vol 4 (5) ◽  
pp. 779-781
Author(s):  
Bron Lett ◽  
Samuel Costello ◽  
Ian Roberts‐Thomson

2019 ◽  
Vol 9 (4) ◽  
pp. 4066-4069 ◽  

An integral part of the intestinal microbiota is undoubtedly formed by lactic acid bacteria (LAB). Their presence in the digestive tract is essential for its proper functioning. During inflammatory bowel disease, such as ulcerative colitis (UC), LAB occurrence is reduced while sulfate-reducing bacteria (SRB) occur widely in the intestine resulting in an increase of their metabolite, hydrogen sulfide. Inhibitory concentration and mechanism of action of hydrogen sulfide on LAB are not fully known yet. The aim of this paper is to find the proper testing methods for evaluation of the interaction between hydrogen sulfide and lactic acid bacteria, including minimal inhibitory concentration (MIC) determination. Spectrophotometric, colorimetric, agar plate methods and combination of these methods were tested. Thousands of people from all over the world are affected by inflammatory bowel disease every year. The gained results could help to understand and improve the stability of intestinal microbiome, improve the treatment of bowel inflammation diseases, or prevent bowel disease altogether


Nutrients ◽  
2021 ◽  
Vol 14 (1) ◽  
pp. 4
Author(s):  
Lara Hart ◽  
Charlotte M. Verburgt ◽  
Eytan Wine ◽  
Mary Zachos ◽  
Alisha Poppen ◽  
...  

Inflammatory bowel disease (IBD) is a chronic, autoimmune disorder of the gastrointestinal tract with numerous genetic and environmental risk factors. Patients with Crohn’s disease (CD) or ulcerative colitis (UC) often demonstrate marked disruptions of their gut microbiome. The intestinal microbiota is strongly influenced by diet. The association between the increasing incidence of IBD worldwide and increased consumption of a westernized diet suggests host nutrition may influence the progression or treatment of IBD via the microbiome. Several nutritional therapies have been studied for the treatment of CD and UC. While their mechanisms of action are only partially understood, existing studies do suggest that diet-driven changes in microbial composition and function underlie the diverse mechanisms of nutritional therapy. Despite existing therapies for IBD focusing heavily on immune suppression, nutrition is an important treatment option due to its superior safety profile, potentially low cost, and benefits for growth and development. These benefits are increasingly important to patients. In this review, we will describe the clinical efficacy of the different nutritional therapies that have been described for the treatment of CD and UC. We will also describe the effects of each nutritional therapy on the gut microbiome and summarize the strength of the literature with recommendations for the practicing clinician.


Sign in / Sign up

Export Citation Format

Share Document